California Supreme Court rejects 'duty-to-innovate' negligence theory
What happened
The California Supreme Court rejected a novel negligence theory that would have allowed plaintiffs to sue manufacturers over nondefective products for failing to develop a safer alternative sooner. In the Gilead Tenofovir Cases, the court held that drug manufacturers do not owe a duty of care to users of a nondefective drug when deciding whether and when to develop a potentially safer alternative.
From mondaq.com
Why it matters
The ruling reaffirms California’s defect-centered framework for negligence claims against product manufacturers. This precedent provides manufacturers across various industries with grounds to reject 'failure-to-innovate' theories based on delayed development of safer products.
From mondaq.com
Who's involved
- Phillips 66A manufacturer potentially affected by the legal precedent limiting product liability risk.
- FordA car brand potentially affected by the legal precedent limiting product liability risk.
- MedicareA federal health insurance program whose liability exposure for drug manufacturers may be affected.
- GoogleA multinational technology company potentially affected by the legal precedent limiting product liability risk.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Phillips 66Speculative
Phillips 66 might see reduced product liability costs for manufacturers operating in California.
- FordSpeculative
Ford might see reduced product liability costs for manufacturers operating in California.
Keep exploring
The entities involved
-
California
Italian singer and disc jockey (born 1990)
-
California
former rapid transit station in Chicago, United States